Back to news

OTraces Selects Labcorp to Perform Biomarker Testing for Florida Department of Health–Funded Prostate Cancer Study

Globe Newswire•18/11/2026•08:30 ET
0

Key Highlights

  • ➤$2 million Florida grant funds 12-month prostate cancer diagnostic trial
  • ➤Labcorp (LH) will test biomarkers for approximately 950 men
  • ➤OTraces selected Labcorp as reference laboratory for clinical trial
  • ➤Testing supports OTraces algorithm evaluating clinically significant prostate cancer risk

Expert Statements

Alain Cappeluti, President, OTraces, Inc.

“Partnering with Labcorp gives us access to a highly scalable, CLIA-certified reference lab infrastructure that is essential for executing a multicenter trial of this size within a 12-month timeline.”

Alain Cappeluti, President, OTraces, Inc.

“Labcorp’s validated assays for IL-6, IL-8, TNF-α, VEGF and PSA align well with our proteomic platform and will support the generation of high-quality, reproducible biomarker data across participating sites in Florida.”

Alain Cappeluti, President, OTraces, Inc.

“By centralizing biomarker testing at Labcorp, we can streamline sample logistics, harmonize processes across Florida sites and generate a robust dataset suitable for clinical validation and eventual commercialization.”

Alain Cappeluti, President, OTraces, Inc.

“This collaboration is designed to produce the level of analytical and clinical rigor that payers, regulators and clinicians expect for next-generation diagnostic tests.”

DEERFIELD BEACH, Fla., Nov. 18, 2026 (GLOBE NEWSWIRE) -- OTraces, Inc., a diagnostics company developing proteomic blood tests for early cancer detection, today announced that it has selected Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, to perform reference laboratory testing for its Florida Department of Health–funded clinical trial evaluating the OTraces blood-based prostate cancer diagnostic platform. The study is supported by a 12-month, $2 million grant awarded under the Florida Cancer Innovation Fund to improve biopsy decision-making for men with elevated prostate-specific antigen (PSA) levels.

Under the agreement, Labcorp will run a panel of serum biomarkers — Interleukin-6 (IL-6, Test 140916), Interleukin-8 (IL-8, Test 140918), Tumor Necrosis Factor-α (TNF-α, Test 140673), Vascular Endothelial Growth Factor (VEGF, Test 117021) and Prostate-specific Antigen (PSA, Test 010322) — on samples collected from approximately 950 men enrolled at Florida clinical sites. These biomarkers feed into the OTraces proprietary algorithm, which is designed to determine the likelihood of clinically significant prostate cancer and thereby reduce unnecessary prostate biopsies.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in